Howmedica Osteonics Corporation

Thomas Jefferson University

James San Antonio

J Brook Burley

Matthew B Havener

David Arazawa

Sarah Elizabeth Smith

Sonny Sheth

Marc Gilles Long

Angela Verrecchio

Barbara P Schick

Matt Havener

Sarah Elisabeth Smith

A bioactive filamentary structure includes a sheath coated with a mixture of synthetic bone graft particles and a polymer solution forming a scaffold structure. In forming such a structure, synthetic bone graft particles and a polymer solution are applied around a filamentary structure. A polymer is precipitated from the polymer solution such that the synthetic bone graft particles and the polymer coat the filamentary structure and the polymer is adhered to the synthetic bone graft particles to retain the graft particles.

Bioactive soft tissue implant and methods of manufacture and use thereof

A method of forming a scaffold is disclosed herein. In some embodiments, a method of forming a scaffold includes dissolving a polymer in a solvent to form a polymer solution; adding additive precipitating agent to the polymer solution; precipitating and expanding the polymer from the polymer solution to form a scaffold; and removing the solvent from the scaffold. In some embodiments, prior to adding the precipitating agent, the method further comprising adding at least one of calcium phosphate or a bioactive additive to the polymer solution to form a mixture including the polymer solution and the at least one of calcium phosphate or bioactive additive.

Methods for forming scaffolds

Heparin-binding peptides are provided of the formula R(XBBXBXYR)RR, R(XBBBXXBXYR)RR, and C(XBBBXXBX)C; wherein X, X, X, and Xare independently selected from the group consisting of hydropathic amino acids; B, B, B, and Bare independently selected from the group consisting of basic amino acids; C is cysteine; Yis zero or one to ten amino acid residues, wherein at least one amino acid residue is proline; n is an integer from one to ten; and R, R, and Rare independently selected segments containing from zero to twenty amino acid residues, provided, at least one of the segments R, R, and Rcomprises at least one hydrophobic amino acid residue. The peptide C(XBBBXXBX)C is optionally cyclized via a disulfide bond formed between cysteine residues. The peptides are administered to reduce plasma LMWH and heparin levels and to reduce the anticoagulant effects of heparin and LMWH. The peptides are also administered to inhibit microbial growth and to inhibit mast cell serine proteases involved in various diseases and disorders. The peptides are also administered as carriers to deliver active agents.

Heparin-binding peptides and uses thereof

The present invention involves peptides of various sequences and sizes and methods of using said peptides with a strong affinity for glycosaminoglycans and proteoglycans, wherein said peptides interact strongly with heparin, other glycosaminoglycans, or proteoglycans (PGs).

Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans

Growing community of inventors

Media, PA, United States of America

James San Antonio